U.S. President Donald Trump plans to impose tariffs on imported computer chips, pharmaceuticals and steel, he said on Monday, ...
President Donald Trump issued executive orders late Friday reviving some of his first term’s anti-abortion policies, like ...
Prolonged rapid eye movement (REM) sleep latency was linked with Alzheimer's disease biomarkers, cross-sectional data showed.
The FDA approved a monthly maintenance dosing of intravenous lecanemab (Leqembi) for early Alzheimer's disease, said ...
GlobalData on MSN11h
Genentech’s Itovebi combo hits overall survival endpoint in HER2- breast cancerThe Phase III trial saw a clinically meaningful benefit in overall survival with a combination of Itovebi alongside Ibrance ...
The US Food and Drug Administration (FDA) has approved a new dosing regimen for LEQEMBI, a treatment for early Alzheimer’s disease, according to Eisai and Biogen Inc. The maintenance dosing will now ...
This article highlights recent developments in healthcare, including the U.S. FDA's approval of Alzheimer's and diabetes ...
The 12-month price targets, analyzed by analysts, offer insights with an average target of $214.78, a high estimate of ...
By Francis Page, Jr. Click here for updates on this story January 28, 2025 (Houston Style Magazine) — Sisters Network® Inc. (SNI), the nation’s only African American breast cancer survivorship ...
Verywell Health on MSN10h
New Maintenance Dosing Option for Alzheimer's Drug Leqembi Offers FlexibilityThe Food and Drug Administration (FDA) has approved a new maintenance dosing schedule for Leqembi, a monoclonal antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback